Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.

ABSTRACT:

Objective

To evaluate the cost-utility of different dosing regimens of PCSK9 inhibitors, added to statin therapy, in patients with hypercholesterolemia or at high cardiovascular risk in China.

Methods

A Markov cohort multistate-transition model was developed from the perspective of the Chinese healthcare system, with a 1-year cycle and lifetime horizon. Treatment effects were derived from a network meta-analysis. Costs, utilities, and mortality data were obtained from published literature and national databases. Both costs and outcomes were discounted at a rate of 5% annually. The primary outcome was the incremental cost-utility ratio (ICUR). The willingness-to-pay (WTP) threshold was set at 1-3 times China's 2024 per capita gross domestic product. One-way, probabilis

SUBMITTER: Hu D 

PROVIDER: S-EPMC12672326 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature